Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Futura MedicalFAMDF Price-to-Tangible-Book is 1.67 as of Aug. 17, 2026, which is 84% below its 10-year median of 10.55. The stock has 5 warning signs investors should review. Among 1,134 Biotechnology companies, Futura Medical ranks better than 96.56% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Futura Medical Price-to-Tangible-Book Related Terms
Futura Medical Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Futura Medical's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FAMDF vs VRTX, REGN, RVMD: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Futura Medical's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Futura Medical Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Futura Medical's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Futura Medical's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Futura Medical (FAMDF) has a Price-to-Tangible-Book of 1.67 as of Aug. 17, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Futura Medical and its competitors. This is 84% below median its historical median of 10.55. Over the past decade, Futura Medical's Price-to-Tangible-Book has ranged from 0.50 to 50.83. According to the industry distribution chart, Futura Medical ranks #39 out of 1134 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Futura Medical's Price-to-Tangible-Book too high?
Futura Medical's current Price-to-Tangible-Book of 1.67 is 84% below median its 10-year median of 10.55. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 50.83. The Biotechnology industry median Price-to-Tangible-Book is 3.18. Futura Medical's value of 1.67 is 47.4% below this industry median. Based on the distribution chart, Futura Medical ranks #39 out of 1134 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Futura Medical's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #39 out of 1134 companies for Price-to-Tangible-Book. This places Futura Medical in the top 3% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.18. Futura Medical's value of 1.67 is 47.4% below this benchmark. Historically, Futura Medical's own Price-to-Tangible-Book has ranged from 0.50 to 50.83 over the past decade. While the company's 10-year median is 10.55 vs. the industry median of 3.18, Futura Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.18, based on 1,134 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Futura Medical's current Price-to-Tangible-Book of 1.67 is 47.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Futura Medical and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Futura Medical's current Price-to-Tangible-Book is 1.67, which is 84% below median its own 10-year median of 10.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Based on GuruFocus' analysis, Futura Medical (FAMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.01 — trading 87.5% below its estimated fair value. The current Price-to-Tangible-Book is 1.67, which is 84% below median its 10-year median of 10.55 and 47.4% below the Biotechnology industry median of 3.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Futura Medical (FAMDF), the current Price-to-Tangible-Book is 1.67 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FAMDF has been successfully added to your 
